NXO-001 is a selective p300 inhibitor designed to avoid the toxicities associated with targeting both p300 and CBP.
View competitors
Nexo Therapeutics is an oncology drug-discovery company using covalent ligand discovery and chemical biology.
Covalent ligand discovery, a CODON ligand library, and target-specific pharmacology guide Nexo Therapeutics' optimization toward drug candidates. The CODON library is designed with low promiscuity and tuned to access transient cryptic pockets. Nexo Therapeutics combines protein structure and computation and uses integrated PK/PD modeling to optimize leads toward drug candidates.
Nexo Therapeutics is an oncology drug-discovery company. It builds a discovery platform for novel oncology therapies around covalent ligand discovery and chemical biology.

Incyclix Bio
incyclixbio.com

Nurix
nurixtx.com

Cajal Therapeutics
cajal-tx.com

Crossbow Therapeutics
crossbowtx.com

Xenetic Biosciences
xeneticbio.com

NovoMedix
novomedix.com

City Therapeutics
citytx.com

Exo Therapeutics

NERx Biosciences

NiKang Therapeutics
nikangtx.com

Plexium
plexium.com

28bio
28bio.com

Jnana Therapeutics
jnanatx.com

NEOK Bio
neokbio.com

NextCure
nextcure.com

Novopyxis
novopyxis.com

Nexosome Oncology

Oncotelic Therapeutics
oncotelic.com

Adcentrx Therapeutics
adcentrx.com

Nested Therapeutics
nestedtx.com
Companies similar to Nexo Therapeutics include Incyclix Bio, Nurix, Cajal Therapeutics and Crossbow Therapeutics.
Nexo Therapeutics was founded in 2022.
Nexo Therapeutics' headquarters is located in Watertown, MA, US.
Nexo Therapeutics' most recent funding round was for $60M (USD) in July 2023.
As of Jul 26, 2023, Nexo Therapeutics has disclosed funding of $60M (USD).
Nexo Therapeutics has 30 employees as of Feb 5, 2024.